Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renal cell carcinoma vaccine - FBM Pharma

Drug Profile

Renal cell carcinoma vaccine - FBM Pharma

Alternative Names: Renal cell cancer vaccine - LipoNova; Renal cell cancer vaccine - Vaccentis; Reniale

Latest Information Update: 28 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Liponova AG
  • Developer FBM-PHARMA
  • Class Cancer vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal cell carcinoma

Most Recent Events

  • 28 Jan 2019 Renal cell carcinoma vaccine is not yet available for Renal cell carcinoma (Adjuvant therapy) in Netherlands (Intradermal)
  • 15 Jun 2015 Renal cell carcinoma vaccine is still in phase-III development in the EU
  • 08 Feb 2014 Registered for Renal cell carcinoma (adjuvant therapy) in Austria (Intradermal) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top